One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study
Alexis Ogdie, Yomei Shaw, Michele Almonte, Ervant J. Maksabedian Hernandez, Bradley Stolshek, Kaleb Michaud
doi : 10.1002/acr2.11530
To describe patients’ perspectives on the burden associated with methotrexate (MTX) or tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis (PsA) and rheumatoid arthritis (RA).
Systemic Lupus Erythematosus May Be a Risk Factor for Antimalarial-Induced Retinopathy Compared With Other Rheumatologic Diseases
Hsin Yen Liu, Gemma Cramarossa, Janet E. Pope
doi : 10.1002/acr2.11531
To describe the pattern and risk factors for antimalarial (AM)-induced retinopathy in patients with rheumatic diseases.
Vaccination rates, perceptions, and information sources in inflammatory arthritis: Comment on the article by Lyon et al
Amnuay Kleebayoon, Viroj Wiwanitkit
doi : 10.1002/acr2.11534
Geographic Variation in Disease Burden and Mismatch in Care of Patients With Rheumatoid Arthritis in the United States
Sharon Dowell, Huifeng Yun, Jeffrey R. Curtis, Lang Chen, Fenglong Xie, Manuela Pedra-Nobre, Dianne Wollaston, Sawsan Najmey, Cynthia Lawrence Elliott, Theresa Lawrence Ford, Heather North, Robin Dore, Soha Dolatabadi, Thaila Ramanujam, Stacy Kennedy, Stephanie Ott, Ilona Jileaeva, Amina Richardson, Jeffrey Kaine, Grace Wright, Gail S. Kerr
doi : 10.1002/acr2.11532
Our objective was to evaluate the factors associated with regional variation of rheumatoid arthritis (RA) disease burden in the US.
Enhancing Care Partnerships Using a Rheumatology Dashboard: Bringing Together What Matters Most to Both Patients and Clinicians
Aricca D. Van Citters, Alysha J. Taxter, Stephanie D. Mathew, Erica Lawson, Joad Eseddi, Vincent Del Gaizo, Jabeen Ahmad, Puneet Bajaj, Stacy Courtnay, Lesley Davila, Brittany Donaldson, Yukiko Kimura, Tzielan Lee, John N. Mecchella, Eugene C. Nelson, Scott Pompa, Doreen Tabussi, Lisa C. Johnson
doi : 10.1002/acr2.11533
Dashboards can support person-centered care by helping people partner with their clinicians to coproduce care based on preferences, shared decision-making, and evidence-based treatments.
Peripheral Blood Biomarkers for Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Systematic Review
Daniel Van Kalsbeek, Rebecca Brooks, Dawson Shaver, Ariadne Ebel, Daniel Hershberger, Cynthia Schmidt, Jill A. Poole, Dana P. Ascherman, Geoffrey M. Thiele, Ted R. Mikuls, Bryant R. England
doi : 10.1002/acr2.11535
Biomarkers have been proposed as tools to aid in the identification and prognostication of interstitial lung disease (ILD) in rheumatoid arthritis (RA). We performed a systematic review of studies evaluating peripheral blood biomarkers and their association with RA-ILD and its prognosis.
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
Dennis McGonagle, Iain B. McInnes, Atul Deodhar, Georg Schett, May Shawi, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, Shihong Sheng, Stephen Xu, Christopher T. Ritchlin, Proton Rahman, Phillip J. Mease
doi : 10.1002/acr2.11537
Previous analyses of pooled DISCOVER-1 and DISCOVER-2 data through Week 24 showed significantly higher rates of dactylitis resolution in patients treated with guselkumab compared with placebo. Here, we investigate associations between dactylitis resolution and other outcomes through 1 year.
